- 2 years ago
17 December 2021
Jazz Pharma is the newest member of Medicines Australia, having joined the industry association as a Class 3 member.
The company made its first foray into the Australian market under its own brand this year after submitting acute myeloid leukaemia (AML) combination VYXEOS (cytarabine/daunorubicin hydrochloride) for ARTG registration.
It joins Beigene as the third Tier 3 company member in the growing industry association.
It takes its membership to 27 Class 1 companies, two Class 2 companies, three Class 3 companies and 11 Class 4 companies – a total of 43 member companies, according to MA’s website.
It also means Jazz is eligible to vote in the upcoming Medicines Australia Board election and to potentially nominate ANZ General Manager Adam Maguire.
The TGA announced it had accepted the application by Jazz Pharma in June for Vyxeos, two months after the company said it submitted the therapy for evaluation.
“This is the first [application] that has been made by the new Australia/New Zealand Jazz affiliate after establishing our direct presence in these regions earlier this year,” Maguire said earlier this year.
In regard to seeking PBS funding, Maguire said the company would “work closely with a wide range of stakeholders to accelerate and optimise access for patients”.
“We are in the process of evaluating pathways for funding including listing on the PBS,” he said.
A specialist in haematology and oncology, Jazz registered a product in Australia last year through Link Medical, based on Sydney’s northern beaches. Link registered Jazz’s DEFITELIO (defibrotide), used in stem-cell transplants, in July 2020.
“Building on five years of positive experience in Australia through our distribution partners, our product expansion in this territory allows us to extend patient access and care,” Maguire said.
“Haematology is the foundation of Jazz’s oncology portfolio, and we are pleased to be working towards Jazz’s aspiration of innovating to improve the lives of patients and their families by pursuing the Marketing Authorisation for Vyxeos Liposomal.”